NaviCyte Scientific Grants Cubist Pharmaceuticals Caco-2 Cell Line License
January 2009. Navicyte
Scientific, a division of LION bioscience Inc., announced that Cubist Pharmaceuticals, Inc. has obtained a non-exclusive,
commercial use license for the Caco-2TM cell line.
Financial details of the transaction were not disclosed. Navicyte
Scientific holds an exclusive commercial use license from the Memorial
Sloan Kettering Institute for Cancer Research.
Apredica LLC, Obtains Caco-2 Commercial Use License From NaviCyte Scientific
December 2008. Apredica LLC, has obtained a non-exclusive license for commercial use of the Caco-2TM cell line. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
August 2008. Navicyte
Scientific, a division of LION bioscience Inc., has granted Genzyme Corporation a world-wide, non-exclusive,
commercial use license for the Caco-2TM cell line.
Financial details of the transaction were not disclosed. Navicyte
Scientific holds an exclusive commercial use license from the Memorial
Sloan Kettering Institute for Cancer Research.
Wolfe Laboratories Inc., Obtains Caco-2 Commercial Use License From NaviCyte Scientific
June 2008. Wolfe Laboratories Inc., has obtained a non-exclusive license for commercial use of the Caco-2TM cell line. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Theravance, Inc. Obtains Caco-2 License
December 2007. Theravance Inc. has obtained a non-exclusive
commercial-use
license for the Caco-2TM cell line. Financial details of
the transaction were not disclosed. Navicyte Scientific holds an
exclusive commercial use license from the Memorial Sloan Kettering
Institute for Cancer Research.
NaviCyte Scientific Grants Merck & Co., Inc. Worldwide Caco-2 License
November 2007. Navicyte
Scientific, a division of LION bioscience Inc., announced that Merck & Co., Inc. has obtained a world-wide, non-exclusive
commercial use
license for the Caco-2TM cell line. Financial details of
the transaction were not disclosed. Navicyte Scientific holds an
exclusive commercial use license from the Memorial Sloan Kettering
Institute for Cancer Research.
NaviCyte Scientific Grants Bristol-Myers Squibb Company a Worldwide Caco-2 License
October 2007. Navicyte
Scientific, a division of LION bioscience Inc., announced that Bristol-Myers Squibb Company has obtained a world-wide, non-exclusive commercial use
license for the Caco-2TM cell line. Financial details of
the transaction were not disclosed. Navicyte Scientific holds an
exclusive commercial use license from the Memorial Sloan Kettering
Institute for Cancer Research.
Zealand Pharma Obtains Caco-2 License From NaviCyte Scientific
October 2007. Zealand Pharma A/S has obtained a non-exclusive license for commercial use of the Caco-2TM cell line. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
September 2007. Navicyte
Scientific announced
that Nastech Pharmaceutical Company Inc. has obtained a non-exclusive license to use the Caco-2TM cell line.
Financial details of the transaction were not disclosed. NaviCyte
Scientific holds an exclusive commercial use license from the Memorial
Sloan Kettering Institute for Cancer Research.
Microbia Obtains Caco-2 Commercial Use License From NaviCyte Scientific
August 2007. Microbia Inc. has obtained a non-exclusive license for commercial use of the Caco-2TM cell line. Financial details of the transaction were not disclosed.
August 2007. Navicyte
Scientific, a division of LION bioscience Inc., announced that
Astellas Pharma Inc. has obtained a world-wide, non-exclusive commercial use
license for the Caco-2TM cell line. Financial details of
the transaction were not disclosed. Navicyte Scientific holds an
exclusive commercial use license from the Memorial Sloan Kettering
Institute for Cancer Research.
NaviCyte Scientific Grants Labopharm Inc. Caco-2 License
August 2007. Navicyte
Scientific announced
that Labopharm Inc. has obtained a non-exclusive license to use the Caco-2TM cell line.
Financial details of the transaction were not disclosed. NaviCyte
Scientific holds an exclusive commercial use license from the Memorial
Sloan Kettering Institute for Cancer Research.
MannKind Corporation Obtains Caco-2 Commercial Use License From NaviCyte Scientific
July 2007. MannKind Corporation has obtained a non-exclusive license for commercial use of the Caco-2TM cell line. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
June 2007. Navicyte Scientific, a division of LION bioscience Inc., announced that PainCeptor Pharma Corporation has obtained a non-exclusive commercial use license for the Caco-2TM cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
Trinity Biosystems Obtains Caco-2 Commercial Use License From NaviCyte Scientific
May 2007. Trinity Biosystems has obtained a non-exclusive license for commercial use of the Caco-2TM cell line. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Navicyte Scientific and the American Type Culture Collection Enter into a Collaboration Agreement for Licensing and Distribution of the Caco-2 Cell Line
March 2007. Navicyte Scientific ("Navicyte") and the American Type Culture Collection ("ATCC") announced that they have entered into a collaboration agreement for the coordination of the licensing and distribution of the Caco-2TM cell line to commercial entities. Under the collaboration, commercial entities shall now be able to obtain a license for use of the Caco-2TM cell line from Navicyte just prior to obtaining Caco-2TM materials from ATCC.
Caco-2TM cells were developed by the Sloan Kettering Institute for Cancer Research and are on deposit with ATCC. ATCC is authorized to distribute these cells into the scientific community for research use and Navicyte currently holds an exclusive commercial license from the Sloan Kettering Institute for Cancer Research for commercial use of the Caco-2TM cell line.
February 2007. Navicyte Scientific, a division of LION bioscience Inc., announced that AstraZeneca has obtained a world-wide, non-exclusive commercial use license for the Caco-2TM cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
Navicyte Scientific Grants Diagnostic Hybrids Inc., an Evaluation License for the Caco-2 Cell Line
February 2007. Diagnostic Hybrids has obtained a non-exclusive evaluation license for commercial use of the Caco-2TM. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Navicyte Scientific Grants Amaxa GmbH a Commercial Use License for the Caco-2 Cell Line
October 2006. NaviCyte Scientific, a division of LION bioscience Inc., announced that it has granted a non-exclusive commercial use license for the Caco-2TM cell line to Amaxa GmbH. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
NaviCyte Scientific Grants Non-Exclusive, Worldwide Caco-2 Commercial Use License to In Vitro Technologies
May 2006. LION bioscience Inc., including its NaviCyte Scientific business division, ("NaviCyte") and In Vitro Technologies Inc. ("IVT") announced that they have reached agreement with respect to IVT's use of Caco-2TM cells acquired by IVT from the American Type Culture Collection (ATCC) in 1997. Caco-2TM cells were developed by the Memorial Sloan-Kettering Institute for Cancer Research and deposited with ATCC subject to commercial restrictions. NaviCyte obtained an exclusive commercial license from the Memorial Sloan-Kettering Institute for commercial use of the cell line 1997.
Under the NaviCyte-IVT agreement, IVT holds a worldwide non-exclusive commercial sublicense from NaviCyte (doing business as NaviCyte Scientific) to use and distribute, as well as the use of Caco-2TM cells in IVT's products and services, subject to end-user restrictions. As part of the agreement, both NaviCyte and IVT also have agreed to withdraw, and to refrain from pursuing all pending claims and counterclaims against each other relating to Caco-2TM.
Additional details of the agreement were not disclosed.
NaviCyte Scientific Successfully Manages Assignment of iDEA Technology and Related Intellectual Property
May 2006. Navicyte Scientific announced that it successfully managed the assignment of the iDEA pkEXPRESS predictive software technology and related assets to a California-based company.
iDEA pkEXPRESS is a comprehensive predictive ADME (absorption, distribution, metabolism and elimination) solution for lead optimization. Inappropriate pharmacokinetic properties have historically caused the failure of compounds in the later stages of development. The software serves as an early stage development tool to help identify chemical compounds that have appropriate ADME properties for later stage development. In this way, iDEA pkEXPRESS enables medicinal chemists and pharmacokinetic researchers involved in drug discovery to select compounds with the best ADME characteristics in order to accelerate lead optimization.
Details of the transaction were not disclosed.
U.S. Pharmaceutical Company Obtains Caco-2 Commercial Use License From NaviCyte Scientific
January 2006. A domestic pharmaceutical company has entered into a world-wide, non-exclusive, commercial use license for the Caco-2TM cell line with NaviCyte Scientific. NaviCyte granted the license under NaviCyte's Caco-2 Up-To-Date program. Terms and conditions of the transaction were not disclosed. For more information on NaviCyte's Caco-2 Up-To-Date program, please click here.
NaviCyte Scientific Successfully Brokers Exclusive Multi-Year License of Melanocortin Receptor Technology and Intellectual Property
July 2005. NaviCyte announced that it has successfully licensed assets resulting from the extensive research and drug discovery program of former Trega Biosciences Inc. involving melanocortin receptors to a San Diego based biotechnology business under an exclusive multi-year worldwide license.
Melanocortin receptors regulate a diverse array of functions in the human body, including sexual arousal, feeding behavior and energy maintenance, inflammation and skin pigmentation. These receptors are considered potential building blocks for the next generation of sexual dysfunction drugs. Trega had used its combinatorial chemistry technologies to discover a family of proprietary compounds that appear to influence the production and activity of certain cytokines through interaction with melanocortin receptors. Trega's research encompassed the development of a number of different compounds active against certain melanocortin receptors, including for the treatment of sexual dysfunction in humans. Trega also pursued a number of key patents giving Trega broad protections of the results from its melanocortin research program.
NaviCyte Scientific was appointed to facilitate the licensing of these assets. Under the terms of the license, the licensee will make minimum annual license fee payments and pay certain royalties.
BD Biosciences Discovery Labware Receives Caco-2 Commercial Use License from NaviCyte Scientific under Caco-2 Up-To-Date Initiative
June 2005. NaviCyte Scientific, a division of LION bioscience Inc., announced that BD Biosciences Discovery Labware, a wholly owned sub of BD Biosciences, a business segment of BD (Becton, Dickinson and Company), one of the largest businesses supporting the life sciences today, has obtained a non-exclusive commercial use license for the Caco-2TM cell line from NaviCyte Scientific under NaviCyte's Caco-2 Up-To-Date Intiative. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date Initiative, please click here.
Novartis Receives Worldwide Caco-2 Commercial Use License from NaviCyte Scientific under Caco-2 Up-To-Date Initiative
June 2005. NaviCyte Scientific, a division of LION bioscience Inc., announced that Novartis, one of the world's leading pharmaceutical companies, has entered into worldwide non-exclusive commercial use license for the Caco-2TM cell line from NaviCyte Scientific under NaviCyte's Caco-2 Up-To-Date Intiative. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date Initiative, please click here.
NaviCyte Scientific Receives Final Royalty Payment on Tea-Bag Technology from IRORI, a Discovery Partners International Company.
May 2005. NaviCyte Scientific, a division of LION bioscience Inc., announced that it has received royalty payments from IRORI, a Discovery Partners International (NASDAQ: DPII) company, with respect to the Tea-Bag Technology of former Trega Bioscienes. In May 1998, Trega had granted IRORI a non-exclusive, worldwide license to its Tea-Bag technology for use in IRORI's Kan(TM)-style family of microreactors. Under the terms of the agreement, IRORI had agreed to pay an upfront licensing fee and a royalty on all Kan(TM)-family product sales. Earlier this year, NaviCyte had facilitated the payment of previously outstanding royalties from IRORI under the license agreement.
Biogen Idec Obtains Caco-2 Commercial Use License from NaviCyte Scientific under Caco-2 Up-To-Date Initiative
March 2005. NaviCyte Scientific, a division of LION bioscience Inc., announced that Biogen Idec, one of the world's leading biotechnology companies, has entered into a non-exclusive commercial use license for the Caco-2TM cell line with NaviCyte Scientific under NaviCyte's Caco-2 Up-To-Date Intiative. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date Initiative, please click here.
NaviCyte Scientific Facilities Payment of Royalties on Tea-Bag Technology from IRORI, a Discovery Partners International Company.
February 2005. NaviCyte Scientific, a division of LION bioscience Inc., announced that it had facilitated the payment of outstanding royalties from IRORI, a Discovery Partners International (NASDAQ: DPII) company, with respect to the Tea-Bag Technology of former Trega Bioscienes. In May 1998, Trega had granted IRORI a non-exclusive, worldwide license to its Tea-Bag technology for use in IRORI's Kan(TM)-style family of microreactors. Under the terms of the agreement, IRORI had agreed to pay an upfront licensing fee and a royalty on all Kan(TM)-family product sales. Trega had acquired the Tea-Bag Technology under an exclusive license agreement with The Scripps Research Institute. NaviCyte Scientific expects additional payments to be paid by IRORI in the future.
NaviCyte Grants Caco-2 Commercial Use License to Millipore and Two Other U.S. Life Sciences Companies
September 2004. NaviCyte Scientific, a division of LION bioscience Inc., announced that it has entered into a non-exclusive commercial use license for the Caco-2TM cell line with Millipore Corporation. The license was entered into under NaviCyte's Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed. In addition, NaviCyte has entered into non-exclusive commercial use licenses with two other life sciences companies under under NaviCyte's Caco-2 Up-To-Date program having a combinged market capitalization of more than US$1.75 billion. Details of these transactions have not been published. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Proctor & Gamble PharmaceuticalsObtains Commercial Use License for Caco-2 from NaviCyte
May 2004. NaviCyte Scientific, a division of LION bioscience Inc., announced that it has granted a non-exclusive commercial use license for the Caco-2(TM) cell line to Proctor & Gamble Pharmaceuticals. The license was entered into under NaviCyte's Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Major Multinational Pharmaceuticals Company Licenses Caco-2 from NaviCyte Scientific
May 2004. A large multinational pharmaceutical company has entered into a global non-exclusive commercial use license for the Caco-2TM cell line with NaviCyte Scientific. NaviCyte granted the license under NaviCyte's Caco-2 Up-To-Date program. Details of the transaction have not been published. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Millennium Pharmaceuticals Acquires Perpetual Commercial Use License for Caco-2 from NaviCyte
March 2004. Millennium Pharmaceuticals has entered into a perpetual non-exclusive commercial use license for the Caco-2TM cell line with NaviCyte Inc. under NaviCyte's Caco-2 Up-To-Date program. Millennium had previously licensed Caco-2 for commercial use from NaviCyte under a term license that Millennium had renewed in September 2003. NaviCyte has now extended the term of the license for a perpetual period in consideration for payment by Millennium of a perpetual use license fee in accordance with NaviCyte's Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed. The Caco-2 cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center and have been deposited with the ATCC for non-commercial research uses only. NaviCyte is the exclusive commercial distributor and licensor of the Caco-2 cell line under an agreement with Memorial Sloan-Kettering. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Abbott Laboratories Obtains Commercial Use License for Caco-2 from NaviCyte
December 2003. NaviCyte Inc., a subsidiary of LION bioscience Inc., is pleased to announce that Abbott Laboratories has obtained a non-exclusive commercial use license for the Caco-2TM cell line from NaviCyte Scientific under NaviCyte's Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed. The Caco-2 cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center and have been deposited with the ATCC for non-commercial research uses only. NaviCyte is the exclusive commercial distributor and licensor of the Caco-2 cell line under an agreement with Memorial Sloan-Kettering. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
Millennium Pharmaceuticals Renews Caco-2 License with NaviCyte
September 2003. NaviCyte, Inc., a subsidiary of LION bioscience Inc., is pleased to announce that Millennium Pharmaceuticals has renewed its non-exclusive commercial use license for the Caco-2TM cell line with NaviCyte. Financial details of the transaction were not disclosed. Millennium had initially entered into a two-year commercial use license with NaviCyte which recently came up for renewal. The Caco-2 cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center and have been deposited with the ATCC for non-commercial research uses only. NaviCyte is the exclusive commercial distributor and licensor of the Caco-2 cell line under an agreement with Memorial Sloan-Kettering. For more information of NaviCyte's Caco-2 Up-To-Date program, please click here.
